Obesity Medicine

Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.

Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.

Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.

Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.

Anila Chadha, MD, talks to Patient Care about how antiobesity medications can aid in reducing CVD risk in patients with obesity.

In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.

Weekly subcutaneous injections of amycretin featured a safety profile similar to other incretin-based drugs, according to new topline results.

Shagun Bindlish, MD, board member of the American Diabetes Association, discusses a recent clinical practice statement she coauthored published in the journal Obesity Pillars.

Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.

The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.

Shagun Bindlish, MD, board member of the American Diabetes Association, details available options for treating venous disease in patients with obesity.

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.

Caissa Troutman, MD, provides an overview of the connection between obesity and hypertension.

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.

President of the Obesity Medicine Association discusses a recent joint statement from the OMA and 4 other organizations calling for inclusion of patients with obesity in drug research.

The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.

Angela Fitch, MD, discusses the importance of clinician education in addressing obesity with patients.

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.